Objetivo The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients. These gene expression signatures will be utilised clinically as non-invasive diagnostic tests for PD. The sensitivity of the newly developed diagnostic test will be determined by extensive validations on independent cohort of PD patients, whereas the specificity will be assessed by testing patients with atypical parkinsonisms, including multiple system atrophy, progressive supranuclear palsy and diffuse Lewy body disease. In order to test the specificity of the diagnostic set in other disorders that affect basal ganglia, Huntington's disease and dopa responsive dystonia patients will be analysed. The second objective of the proposal is to determine correlations between gene expression signatures and different stages of PD and thus provide the basis for early diagnosis and monitoring of disease progression. These changes in blood gene expression will be correlated with alterations detected by neuroimaging in the brain of PD patients. Such combinations of molecular and morphological markers of disease may ultimately facilitate the selection and monitoring of neuroprotective therapies for PD. Finally, GENEPARK aims to develop new bioinformatic software tools for selection of genomic biomarkers using microarray data. A set of established computational tools will be applied and novel methods, some of them based on mechanistic modelling of the neurodegenerative diseases, will be developed in order to study the advantages and limitations of the different methodologies. With special emphasis on careful clinical selection of patients and sufficient power regarding patient numbers, as well as extensive quality control and validation of the data, GENEPARK aims to develop a standardised approach to development and validation of haemogenomic biomarkers of disease. Ámbito científico natural sciencesbiological sciencesgeneticsnatural sciencescomputer and information sciencessoftwaremedical and health sciencesbasic medicineneurologyparkinson Programa(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Tema(s) LSH-2005-1.2.2-2 - Development of innovative methods for diagnosis of nervous system disorders Convocatoria de propuestas FP6-2005-LIFESCIHEALTH-6 Consulte otros proyectos de esta convocatoria Régimen de financiación STREP - Specific Targeted Research Project Coordinador UNIVERSITY MEDICAL CENTER LJUBLJANA Aportación de la UE Sin datos Dirección Zaloska cesta 2 LJUBLJANA Eslovenia Ver en el mapa Coste total Sin datos Participantes (7) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo UNIVERSITY OF LUEBECK Alemania Aportación de la UE Sin datos Dirección Ratzeburger Allee 160 LUEBECK Ver en el mapa Coste total Sin datos MEDITERANEAN INSTITUTE FOR LIFE SCIENCES Croacia Aportación de la UE Sin datos Dirección Mestrovicevo setaliste bb SPLIT Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos PROGENIKA BIOPHARMA S.A. España Aportación de la UE Sin datos Dirección Parque Tecnologico Zamudio, 801-B DERIO Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos EBERHARD-KARLS-UNIVERSITY TUEBINGEN Alemania Aportación de la UE Sin datos Dirección Wilhelmstr. 5 TUEBINGEN Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos TEL AVIV UNIVERSITY Israel Aportación de la UE Sin datos Dirección Ramat Aviv 39040 TEL AVIV Ver en el mapa Coste total Sin datos RR & CO. PODJETJE ZA POSLOVNE STORITVE, D.O.O. Eslovenia Aportación de la UE Sin datos Dirección Dunajska cesta 20 LJUBLJANA Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Francia Aportación de la UE Sin datos Dirección 101 rue de Tolbiac PARIS Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos